Pharmacodynamic properties of leukotriene receptor antagonists

Monaldi Archives for Chest Disease

Volumn 54, Issue 3, 1999, Pages 242-246

  Nicosia, S ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Accolate; Asthma; Leukotriene; Leukotriene C4; Leukotriene D4; Montelukast; Receptor antagonists; Singulair; Zafirlukast

Indexed keywords

1 [2 METHOXY 4 [(PHENYLSULFONYLAMINO)CARBONYL]BENZYL] 1H INDAZOLE 6 CARBAMIC ACID CYCLOPENTYL ESTER; 2 [4 [2 (5 TETRAZOLYLMETHYL)BENZYLOXY]PHENOXYMETHYL]QUINOLINE; 3 [(2 CARBOXYETHYL)THIO] 3 [2 (8 PHENYLOCTYL)PHENYL]PROPIONIC ACID; 6 (4 CARBOXYPHENYLTHIO) 5 HYDROXY 7,9,11,14 ICOSATETRAENOIC ACID; 7 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY) 2 HYDROXYPROPOXY] 4 OXO 8 PROPYL 4H 1 BENZOPYRAN 2 CARBOXYLIC ACID; ACETYLSALICYLIC ACID; ALPHA PENTYL 3 (2 QUINOLYLMETHOXY)BENZYL ALCOHOL; ANTIHISTAMINIC AGENT; BAX 7195; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CGP 44826; CINALUKAST; IBUDILAST; IRALUKAST; LEUKOTRIENE; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; MEPYRAMINE; MONTELUKAST; PEPTIDOLEUKOTRIENE; POBILUKAST; PRANLUKAST; RECEPTOR SUBTYPE; SULUKAST; TOMELUKAST; UNCLASSIFIED DRUG; VERLUKAST; ZAFIRLUKAST;

ARTICLE; ASTHMA; BRONCHOSPASM; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; EXERCISE INDUCED ASTHMA; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

EID: 0032792473     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Centers for Disease Control. - Asthma - United States, 1980-1990. J Am Med Assoc 1992; 268: 1995-1999.
2. Barnes PJ. - Frontiers in medicine. New aspects of asthma. J Internal Med 1992; 231: 453-461.
3. Samuelsson B. -Leukotrienes: a new class of mediators of immediate hypersensitivity reactions and inflammation. Adv Prostaglandin Thromboxane Leukot Res 1983; 11: 1-13.
4. Drazen JM, Austen KF. - Leukotrienes and airway responses. Am Rev Respir Dis 1987; 136: 985-998.
5. Hay DWP, Torphy TJ, Undem BJ. - Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Phannacol Sci 1995; 16: 304-309.
6. 4 and asthma. Thorax 1996; 51: 1171-1173.
7. 4 that mediates chemotaxis. Nature 1997; 387: 620-624.
8. Coleman RA, Eglen RM, Jones RL, et al. - Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv Prostaglandin Thromboxane Leukot Res 1995; 23: 283-285.
9. 4. Fed Proc 1987; 46: 200-203.
10. Salmon JA, Garland LG. -Leukotriene antagonists and inhibitors of leukotriene biosynthesis as potential therapeutic agents. Prog Drug Res 1991; 37: 9-90.
11. Augstein J, Farmer JB, Lee TB, Sheard P, Tattersall ML. - Selective inhibitor of slow reacting substance of anaphylaxis. Nature 1973; 245: 215-217.
12. 4 antagonist. J Phannacol Exp Ther 1985; 233: 148-157.
13. Hay DWP, Muccitelli RM, Tucker SS, et al. - Pharmacologic profile of SK&F 104353: a novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways. J Pharmacol Exp Ther 1987; 243: 474-481.
14. Snyder DW, Giles RE, Keith RA, Yee YK, Krell RD. - In vitro pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist. J Pharmacol Exp Ther 1987; 243: 548-556.
15. Krell RD, Aharony D, Buckner CK, et al. - The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist. Am Rev Respir Dis 1990; 141: 978-987.
16. 4 antagonist: pharmacological characterization in vitro and in vivo in the guinea pig. Prostaglandins Leukot Essent Fatty Acids 1989; 37: 97-106.
17. Jones TR, Zamboni R, Belley M, et al. - Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 1989; 67: 17-28.
18. 4 receptor antasonist. Can J Physiol Phannacol 1995; 73: 191-201.
19. O'Donnell M, Crowley HJ, Yaremko B, O'Neill N, Welton AF. - Pharmacologic actions of Ro 24-5913, a novel antagonist of leukotriene D4. J Phannacol Exp Tlier 1991; 259: 751-758.
20. 4 and antigen in vitro. Am Rev Respir Dis 1992; 146: 923-929.
21. 4 antagonist in the guinea pig trachea. Ann N Y Acad Sci 1991; 629: 402-404.
22. Nicosia S, Capra V, Accomazzo MR, et al. - Receptors and second messengers for Cys-leukotrienes. In: Folco GC, Samuelsson B, Maclouf J, Velo GP, eds. Eicosanoids: from Biotechnology to Therapeutic Applications. New York, Plenum Press, 1996; pp. 127-136.
23. Tudhope SR, Cuthbert NJ, Abram TS, et al. - BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes. Eur J Phannacol 1994; 264: 317-323.
24. Gardiner PJ, Abram TS, Tudhope SR, Cuthbert NJ, Norman P, Brink C. - Leukotriene receptors and their selective antagonists. Adv Prostaglandin Thromboxane Leukot Res 1994; 22: 49-61.
25. Brooks CDW, Summers JB. - Modulators of leukotriene biosynthesis and receptor activation. J Med Chem 1996; 39: 2629-2654.
26. Folco GC, Buccellati C, Testa T, Bolla M, Sala A. - Leukotriene antagonists and synthetase inhibitors; clinical applications in the treatment of bronchial asthma. In; Folco GC, Samuelsson B, Maclouf J, Velo GP, eds. Eicosanoids: from Biotechnology to Therapeutic Applications. New York, Plenum Press, 1996; pp. 165-182.
27. Rabe KF. -Leukotrienes in induced airway obstruction. In: Rodger I, Botting J, Dahlen S-E, eds. Leukotrienes, New Concepts and Targets for Therapy. London, Kluwer Academic Publishers, 1998; pp.73-78.
28. Lams BEA, Lee TH. - Influence of leukotrienes and anti-leukotrienes on airway tone and migration of inflammatory cells. In: Rodger I, Botting J, Dahlen S-E, eds. Leukotrienes, New Concepts and Targets for Therapy. London, Kluwer Academic Publishers, 1998; pp. 55-62.
29. Barnes NC, Macfarlane AJ. - Leukotrienes in airways obstruction and inflammation evoked by allergen. In: Rodger I, Bolting J, Dahlen S-E, eds. Leukotrienes, New Concepts and Targets for Therapy. London, Kluwer Academic Publishers, 1998; pp. 63-72.
30. Szczeklik A, Sanak M. -Role of leukotrienes in aspirin-induced asthma. In: Rodger I, Botting J, Dahlen S-E, eds. Leukotrienes, New Concepts and Targets for Therapy. London, Kluwer Academic Publishers, 1998; pp. 79-88.
31. Dahlén S-E. - Leukotrienes as mediators in aspirin-induced asthma. AIANE Newsletter 1994; 4: 1-3.
32. 4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350: 1599-1600.
33. Lee TH. - Mechanism of bronchospasm in aspirin-sensitive asthma. Am Rev Respir Dis 1993; 148: 1442-1443.
34. 4-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1991; 88: 193-198.
35. 4, methacholine, and histamine. Am Rev Respir Dis 1990; 142: 1112-1118.
36. Hui KP, Barnes NC. - Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1997; 337: 1062-1063.
37. 4 antagonist MK-476. Am J Respir Crit Care Med 1994; 149: A216.
38. Lewis MA, Krell RD, Jones TR. - Third-generation peptidoleukotriene receptor antagonists. In: Crooke ST, Wong A, eds. Lipoxygenases and their Products. San Diego, Academic Press, 1991; pp. 207-234.
39. Roquet A, Dahlen B, Kumlin M, et al. - Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997; 155: 1856-1863.
40. Reiss TF, Sorkness CA, Stricker W, et al. - Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997; 52: 45-48.
41. Calhoum WJ, Lavins BJ, Glass M. - Effect of Accolate (zafirlukast) on bronchoalveolar lavage fluid (BAL) after segmental antigen bronchoprovocation (SBP) in patients with mild to moderate asthma. Am J Respir Crit Care Med 1995; 151(4): A42.